Skip to main content
All lobbying clients

ORCHARD THERAPEUTICS NORTH AMERICA

Lobbying client · Massachusetts · filed 2025 to 2026

Health

$1,840,000 Reported spend
7 Filings counted
1 Firms hired
5 Bills named

Spend is reported income plus in-house expenses across 7 filings. 2 further filings on this record were restated by a later amendment and are left out of every total here. Everything on this page is grouped by the client's LDA id (61639), not by name.

 Firms hired 1
 Bills named in these filings 5
  • HR 1262
    Mikaela Naylon Give Kids a Chance Act
    4 filings
  • HR 1509
    Accelerating Kids’ Access to Care Act of 2025
    3 filings
  • HR 7871
    MVP Act
    2 filings
  • HR 2666
    Medicaid VBPs for Patients Act
    1 filing
  • S 1637
    MVP Act
    1 filing
 Reported by year 2 years
  • 2026 $660,000 2 filings
  • 2025 $1,180,000 5 filings
 Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 5
  • HOUSE OF REPRESENTATIVES 6
  • SENATE 6
  • Health & Human Services, Dept of (HHS) 4
  • Food & Drug Administration (FDA) 3
  • Centers For Medicare and Medicaid Services (CMS) 2
 Recent filings 9 total
Q2
ORCHARD THERAPEUTICS NORTH AMERICA
2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $190,000 expenses · posted Jul 17, 2026
View → 1A
ORCHARD THERAPEUTICS NORTH AMERICA
1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $470,000 expenses · posted Apr 29, 2026
View → Q1
ORCHARD THERAPEUTICS NORTH AMERICA Amended
1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $350,000 expenses · posted Apr 17, 2026
View → 2A
ORCHARD THERAPEUTICS NORTH AMERICA
2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $430,000 expenses · posted Mar 13, 2026
View → Q4
ORCHARD THERAPEUTICS NORTH AMERICA
4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $260,000 expenses · posted Jan 20, 2026
View → Q3
ORCHARD THERAPEUTICS NORTH AMERICA
3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $220,000 expenses · posted Oct 16, 2025
View → RA
ORCHARD THERAPEUTICS NORTH AMERICA
3rd Quarter (July 1 - Sep 30) 2025 · posted Sep 16, 2025
View → Q2
ORCHARD THERAPEUTICS NORTH AMERICA Amended
2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $220,000 expenses · posted Jul 17, 2025
View → Q1
ORCHARD THERAPEUTICS NORTH AMERICA
1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $270,000 expenses · posted Apr 18, 2025
View →
 Foreign entities disclosed 3
  • KYOWA KIRIN INTERNATIONAL PLC United Kingdom named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0
  • ORCHARD THERAPEUTICS (EUROPE) LIMITED United Kingdom named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $880,000
  • ORCHARD THERAPEUTICS LIMITED United Kingdom named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem